지원사업
학술연구/단체지원/교육 등 연구자 활동을 지속하도록 DBpia가 지원하고 있어요.
커뮤니티
연구자들이 자신의 연구와 전문성을 널리 알리고, 새로운 협력의 기회를 만들 수 있는 네트워킹 공간이에요.
논문 기본 정보
- 자료유형
- 학술저널
- 저자정보
- 발행연도
- 2017.1
- 수록면
- 230 - 238 (9page)
이용수
초록· 키워드
오류제보하기
Background/Aims: Tenofovir disoproxil fumarate (TDF) monotherapy for 48 weeks provided a virological response comparable to that of TDF and entecavir (ETV) combination therapy in patients infected with ETV-resistant hepatitis B virus (HBV). Little long-term data in routine clinical practice are available regarding the optimal treatment of patients with ETV-resistant HBV.
Methods: We investigated the long-term antiviral efficacy of combination therapy of TDF+lamivudine (LAM) or TDF+ETV compared to that of TDF monotherapy in 73 patients with resistance to both LAM and ETV.
Results: Patients were treated with TDF monotherapy (n=12), TDF+LAM (n=19), or TDF+ETV (n=42) for more than 6 months. The median duration of TDF-based rescue therapy was 37 months. Virologic response (VR) was found in 63 patients (86.3%). The rates of VR among the three groups (TDF monotherapy, TDF+LAM, and TDF+ETV) were not statistically different (log-rank P=0.200) at 12 months (59.3%, 78.9%, and 51.8%, respectively) or at 24 months (88.4%, 94.7%, and 84.2%). In addition, treatment efficacy of TDF-based combination or TDF monotherapy was not statistically different with ETV-resistant strains or exposure to other antiviral agents. In multivariate analysis, only lower baseline HBV DNA level was an independent predictor for VR (hazard ratio, 0.723; 95% confidence interval, 0.627-0.834; P<0.001).
Conclusions: TDF monotherapy was as effective as combination therapy of TDF+LAM or TDF+ETV in maintaining long-term viral suppression in chronic hepatitis B patients with resistance to both LAM and ETV. HBV DNA level at the start of TDF rescue therapy was the only independent predictor of subsequent VR.
목차
등록된 정보가 없습니다.
참고문헌 (24)
참고문헌 신청
Chang TT / 2010 / Long-term entecavir therapy results in the reversal of fibrosis/cirrhosis and continued histological improvement in patients with chronic hepatitis B / Hepa
Chen CJ / 2006 / Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level / JAMA 295 : 65 ~ 73
European Association For The Study Of The Liver / 2012 / Easl clinical practice guidelines: Management of chronic hepatitis B virus infection / J Hepatol 57 : 167 ~ 185
Ghany MG / 2009 / Antiviral resistance and hepatitis B therapy / Hepatology 49 (5 Suppl) : S174 ~ S184
Hosaka T / 2013 / Long-term entecavir treatment reduces hepatocellular carcinoma incidence in patients with hepatitis B virus infection / Hepatology 58 : 98 ~ 107
Chen CJ / 2006 / Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level / JAMA 295 : 65 ~ 73
European Association For The Study Of The Liver / 2012 / Easl clinical practice guidelines: Management of chronic hepatitis B virus infection / J Hepatol 57 : 167 ~ 185
Ghany MG / 2009 / Antiviral resistance and hepatitis B therapy / Hepatology 49 (5 Suppl) : S174 ~ S184
Hosaka T / 2013 / Long-term entecavir treatment reduces hepatocellular carcinoma incidence in patients with hepatitis B virus infection / Hepatology 58 : 98 ~ 107
함께 읽어보면 좋을 논문
논문 유사도에 따라 DBpia 가 추천하는 논문입니다. 함께 보면 좋을 연관 논문을 확인해보세요!
-
Comparison of tenofovir plus lamivudine versus tenofovir monotherapy in patients with lamivudine-resistant chronic hepatitis B
Clinical and Molecular Hepatology
2016 .01
-
The efficacy of Tenofovir-based therapy in patients showing suboptimal response to Entecavir-Adefovr combination therapy
Clinical and Molecular Hepatology
2016 .01
-
Management of Antiviral Resistance in Chronic Hepatitis B
Gut and Liver
2017 .01
-
Entecavir plus tenofovir versus entecavir plus adefovir in chronic hepatitis B patients with a suboptimal response to lamivudine and adefovir combination therapy
Clinical and Molecular Hepatology
2015 .01
-
Effects of Entecavir and Tenofovir on Renal Function in Patients with Hepatitis B Virus-Related Compensated and Decompensated Cirrhosis
Gut and Liver
2017 .01
-
Entecavir versus Tenofovir for the Prevention of Hepatocellular Carcinoma in Treatment-naïve Chronic Hepatitis B Patients in Korea
Journal of Korean Medical Science
2021 .01
-
Tenofovir and Entecavir Have Similar Renal Adverse Events on Hepatocellular Carcinoma Patients Treated with Transarterial Chemoembolization
Journal of Liver Cancer
2019 .01
-
Entecavir versus tenofovir in patients with chronic hepatitis B: Enemies or partners in the prevention of hepatocellular carcinoma
Clinical and Molecular Hepatology
2021 .01
-
The effect of nucleos(t)ide analogues on clinical outcomes of patients treated with transarterial chemoembolization and radiofrequency ablation for hepatitis B virus-related hepatocellular carcinoma
Journal of Liver Cancer
2021 .09
-
Tenofovir-associated nephrotoxicity in patients with chronic hepatitis B: Two cases
Clinical and Molecular Hepatology
2016 .01
-
Impact of Lamivudine Experience on the Antiviral Efficacy and Resistance Development of Entecavir in Chronic Hepatitis B Patients
Clinical and Molecular Hepatology
2015 .01
-
Long-term Nucleotide Analogue Treatment Has Higher Levels of Renal Toxicities than Does Entecavir in Patients with Chronic Hepatitis B
Gut and Liver
2020 .01
-
Efficacy and safety of entecavir versus lamivudine over 5 years of treatment: A randomized controlled trial in Korean patients with hepatitis B e antigen-negative chronic hepatitis B
Clinical and Molecular Hepatology
2017 .01
-
Nucleos(t)ide Analogues for Reducing Hepatocellular Carcinoma in Chronic Hepatitis B Patients: A Systematic Review and Meta-Analysis
Gut and Liver
2020 .01
-
Tenofovir-induced renal tubular dysfunction among human immunodeficiency virus patients on antiretroviral therapy in Nigeria: Prospects for early detection of presymptomatic nephrotoxicity
Kidney Research and Clinical Practice
2018 .01
-
Efficacy of prolonged entecavir monotherapy for partial virologic response to entecavir in treatment-naïve chronic hepatitis B patients
Clinical and Molecular Hepatology
2015 .01
-
Entecavir+tenofovir vs. lamivudine/telbivudine+adefovir in chronic hepatitis B patients with prior suboptimal response
Clinical and Molecular Hepatology
2020 .01
-
A severe case of tenofovir-associated acute kidney injury requiring hemodialysis in a patient with chronic hepatitis B
Kidney Research and Clinical Practice
2020 .01
-
The Incidence and Clinical Characteristics of Acute Serum Creatinine Elevation more than 1.5 mg/dL among the Patients Treated with Tenofovir/ Emtricitabine-containing HAART Regimens
Infection and Chemotherapy
2015 .01
-
Clinical characteristics of patients with chronic hepatitis B who developed genotypic resistance to entecavir: Real-life experience
Clinical and Molecular Hepatology
2017 .01
이 논문의 저자 정보
최근 본 자료
댓글(0)
0